Kimiteru Ito1,2, Heiko Schöder3, Rebecca Teng1, John L Humm4, Ai Ni5, Jedd D Wolchok6, Wolfgang A Weber1,7. 1. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. 3. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. schoderh@mskcc.org. 4. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 6. Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 7. Department of Nuclear Medicine, Technical University of Munich, Marchioninistraße 15, 81377, Munich, Germany.
Abstract
PURPOSE: Ipilimumab induces durable remission in about 15-20% of patients with metastatic melanoma. However, reliable predictors of response to ipilimumab are currently lacking. Whole-body metabolic tumor volume (wMTV) has been shown to be a strong prognostic factor in a variety of malignancies treated with chemotherapy, but few results have been reported for patients treated with immunotherapy. The purpose of this study was to investigate the prognostic value of wMTV and other metabolic parameters from baseline 18F-FDG PET/CT scans in patients with melanoma being treated with ipilimumab. METHODS: The prognostic impact of wMTV, as well as mean standardized uptake values and total lesion glycolysis, was evaluated in 142 consecutive patients with melanoma treated with single-agent ipilimumab therapy. Metabolic parameters were dichotomized by their respective medians and correlated with overall survival (OS). In addition, the prognostic value of metabolic parameters combined with known clinical prognostic factors was evaluated in multivariate analyses. RESULTS: The median OS time in all patients was 14.7 months (95% CI 10.45-18.93 months). wMTV was a strong independent prognostic factor for OS (p = 0.001). The median survival in patients with a metabolic volume above the median was 10.8 months (95% CI 5.88-15.81 months) as compared with 26.0 months (95% CI 3.02-49.15 months) in patients with an MTV below the median. A multivariate model including wMTV and known clinical prognostic factors, such as age and the presence of brain metastases, further improved the identification of patient subgroups with different OS times. CONCLUSION: wMTV appears to be a strong independent prognostic factor in melanoma patients treated with ipilimumab, and can be determined semiautomatically from routine 18F- FDG PET/CT scans. wMTV, combined with clinical prognostic factors, could be used to personalize immunotherapy and in future clinical studies.
PURPOSE:Ipilimumab induces durable remission in about 15-20% of patients with metastatic melanoma. However, reliable predictors of response to ipilimumab are currently lacking. Whole-body metabolic tumor volume (wMTV) has been shown to be a strong prognostic factor in a variety of malignancies treated with chemotherapy, but few results have been reported for patients treated with immunotherapy. The purpose of this study was to investigate the prognostic value of wMTV and other metabolic parameters from baseline 18F-FDG PET/CT scans in patients with melanoma being treated with ipilimumab. METHODS: The prognostic impact of wMTV, as well as mean standardized uptake values and total lesion glycolysis, was evaluated in 142 consecutive patients with melanoma treated with single-agent ipilimumab therapy. Metabolic parameters were dichotomized by their respective medians and correlated with overall survival (OS). In addition, the prognostic value of metabolic parameters combined with known clinical prognostic factors was evaluated in multivariate analyses. RESULTS: The median OS time in all patients was 14.7 months (95% CI 10.45-18.93 months). wMTV was a strong independent prognostic factor for OS (p = 0.001). The median survival in patients with a metabolic volume above the median was 10.8 months (95% CI 5.88-15.81 months) as compared with 26.0 months (95% CI 3.02-49.15 months) in patients with an MTV below the median. A multivariate model including wMTV and known clinical prognostic factors, such as age and the presence of brain metastases, further improved the identification of patient subgroups with different OS times. CONCLUSION: wMTV appears to be a strong independent prognostic factor in melanomapatients treated with ipilimumab, and can be determined semiautomatically from routine 18F- FDG PET/CT scans. wMTV, combined with clinical prognostic factors, could be used to personalize immunotherapy and in future clinical studies.
Entities:
Keywords:
CTLA-4; Ipilimumab; Melanoma; Metabolic tumor volume; PET
Authors: Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Kyoungjune Pak; Gi Jeong Cheon; Hyun-Yeol Nam; Seong-Jang Kim; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee Journal: J Nucl Med Date: 2014-04-21 Impact factor: 10.057
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi Journal: N Engl J Med Date: 2015-04-20 Impact factor: 91.245
Authors: E Bastiaannet; O S Hoekstra; J R de Jong; A H Brouwers; A J H Suurmeijer; H J Hoekstra Journal: Eur J Nucl Med Mol Imaging Date: 2012-07-17 Impact factor: 9.236
Authors: David Chardin; Marie Paquet; Renaud Schiappa; Jacques Darcourt; Caroline Bailleux; Michel Poudenx; Aurélie Sciazza; Marius Ilie; Jonathan Benzaquen; Nicolas Martin; Josiane Otto; Olivier Humbert Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751